 |
 Video: What is a Stock Split?
|
|
|
| ImmunityBio is a clinical-stage biotechnology company developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. Co.'s platforms include: antibody cytokine fusion proteins, which include Anktiva™, a class of biopharmaceuticals that improve the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response; and DNA, RNA, and recombinant protein vaccine technologies, which are for infectious diseases to target key viruses, including coronavirus, and for oncology to deliver tumor-associated antigens, and neoepitopes (expressed only by cancer cells). According to our ImmunityBio stock split history records, ImmunityBio has had 0 splits. | |
|
ImmunityBio (IBRX) has 0 splits in our ImmunityBio stock split history database.
Looking at the ImmunityBio stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ImmunityBio shares, starting with a $10,000 purchase of IBRX, presented on a split-history-adjusted basis factoring in the complete ImmunityBio stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/29/2015 |
|
| End date: |
05/02/2024 |
|
| Start price/share: |
$34.99 |
|
| End price/share: |
$8.97 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-74.36% |
|
| Average Annual Total Return: |
-14.38% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,563.77 |
|
| Years: |
8.77 |
|
|
|
|
|
